• Title/Summary/Keyword: 위축성 위염

Search Result 15, Processing Time 0.025 seconds

The Role of Serum Pepsinogen and Gastrin Test for the Detection of Gastric Cancer in Korea (한국인 위암 진단에 있어 혈청 펩시노겐과 혈청 가스트린 검사의 역할)

  • Kim, Na-Young
    • Journal of Gastric Cancer
    • /
    • v.9 no.3
    • /
    • pp.78-87
    • /
    • 2009
  • Serum pepsinogen (sPG) is a marker of gastric mucosal atrophy, a condition that has been associated with an increased risk of gastric neoplasia. A low sPGI level and a low PG I/II ratio have been associated with severe gastric atrophy, and are frequently found in gastric cancer. Because the prevalence of gastric cancer is high in Korea, it would be convenient if a good biomarker for gastric cancer were developed. Two studies recently investigated the efficacy of sPG along with Helicobacter pylori (H. pylori) as a screening tool for gastric cancer. In these studies, sPG was measured using a Latex enhanced Turbidimetric Immunoassay. We found that H. pylori IgG status, age and gender were associated with serum pepsinogen levels. Thus, to increase the ability of the PG I/II ratio to detect atrophic gastritis, the cutoff value for the PG I/II ratio should be stratified according to the H. pylori IgG status. In addition, a PG I/II ratio ($\leq3.0$), which has been widely used as an international standard for gastric cancer, was found to be a reliable marker for the detection of gastric dysplasia or gastric cancer, especially of the intestinal type. The efficacy of the test in Korea was lower than the efficacy in Japan. However, the detecting power of a PG I/II ratio ($\leq3.0$) was significantly increased in the presence of H. pylori. The ratio together with H. pylori psotivitiy could provide a means of identifying persons at high risk of developing gastric cancer in Korea.

  • PDF

Gastric Adenocarcinoma in Patient with Pernicious Anemia: A Case Report (악성 빈혈환자에서 발병한 위암 1예 보고)

  • Kim, Byung-Soo;Kim, Jong-Won;Lee, In-Kyu;Kim, Dong-Chul;Kim, Woo Ho;Lee, Hyuk-Joon;Yang, Han-Kwang
    • Journal of Gastric Cancer
    • /
    • v.7 no.1
    • /
    • pp.38-41
    • /
    • 2007
  • Increased risk of gastric cancer has been reported in patients with chronic atrophic gastritis that develops in conjunction with pernicious anemia. We report here a case of a gastric adenocarcinoma associated with pernicious anemia. A 40-year-old female patient had been diagnosed with anemia 6 years earlier at a local hospital. One month ago, she visited our hospital for aggravated dizziness and newly developed epigastric soreness. Her blood hemoglobin level was 4.2 g/dl, and a gastroscopic work-up for anemia discovered a 2.5-cm-sized, slightly elevated mucosal lesion at the anterior wall of the high body in the stomach. The biopsy of this lesion revealed a moderately-differentiated adenocarcinoma. She underwent a total gastrectomy with a Roux en Y esophagojejunostomy with D2 lymph node dissection. The final stage of the gastric carcinoma was identified as T1N0M0. Based on this experience, we recommend that a follow-up gastroscopy be performed in patients with pernicious anemia with atrophic gastritis because of the increased risk of gastric cancer in patients with pernicious anemia.

  • PDF

Effect of Helicobacter pylori Eradication on the Prevention of Gastric Cancer in the General Population with or without Precancerous Lesions: A Meta-analysis (일반 인구 집단에서 전암성 병변 유무에 따른 헬리코박터 제균 치료의 위암 예방 효과 연구: 메타분석)

  • Kang, Soo Jin;Shin, Cheol Min;Kang, Seung Joo
    • Journal of Digestive Cancer Reports
    • /
    • v.8 no.2
    • /
    • pp.81-90
    • /
    • 2020
  • We performed a comprehensive meta-analysis on whether Helicobacter pylori (H. pylori) eradication can prevent gastric cancer in individuals with precancerous lesions (chronic atrophic gastritis, intestinal metaplasia, and dysplasia). The studies evaluating the effect of H. pylori eradication on gastric cancer were searched from PubMed, KoreaMed, EMBASE, and Cochrane Library. Subgroup analyses by precancerous lesions, regions and follow-up time were performed. Six randomized clinical trials were included. In the overall population, H. pylori eradication significantly decreased the risk of gastric cancer (risk ratio [RR]=0.56; 95% confidence interval [CI]: 0.41-0.77, p<0.01). Eradication therapy significantly reduced the risk of gastric cancer in Asian and group who followed up more than 10 years (RR=0.51; 95% CI: 0.35-0.73, p<0.01; I2=0%, p=0.46). However, subgroup analysis according to the precancerous lesions did not show any significant results (p>0.05). In the general population especially in Asian population, H. pylori eradication can reduce the risk of gastric cancer. The effect of the eradication treatment is remarkable upon the long-term follow-up. In contrast, there is insufficient evidence whether the eradication should be recommended for the individuals with precancerous lesions.

A Case study on the improvement in atrophic gastritis patient using Ortho-Cellular Nutrition Therapy (OCNT) (세포교정영양요법(OCNT)을 이용한 위축성 위염 환자 개선 사례 연구)

  • KangHwa Lee
    • CELLMED
    • /
    • v.13 no.16
    • /
    • pp.60.1-60.3
    • /
    • 2023
  • Objective: Case report on the improvement of atrophic gastritis through application of Ortho-Cellular Nutrition Therapy (OCNT) Method: OCNT was applied to a Korean female in her 40s suffering from severe atrophic gastritis. Results: Atrophic gastritis was improved following the implementation of OCNT. Conclusion: Application of OCNT can be helpful in alleviation of symptoms in patients displaying atrophic gastritis symptoms.

Do We Have to Treat Helicobacter pylori for Elderly Patients to Prevent Gastric Cancer? (고령 환자에서 위암 발병 감소를 위해 헬리코박터 제균 치료를 해야 하는가?)

  • Park, Seon-Young
    • The Korean journal of helicobacter and upper gastrointestinal research
    • /
    • v.18 no.3
    • /
    • pp.215-216
    • /
    • 2018
  • 위암의 발병률이 감소하고 있기는 하지만 전 세계적으로 여전히 연 100만 명 이상이 새롭게 위암으로 진단되고 있으며, 앞으로 향후 몇십 년 동안은 인구의 고령화로 인하여 위암에 대한 사회적 경제적 부담이 줄어들지 않을 것으로 추측된다. 최근 메타분석에서 Helicobacter pylori 제균 치료가 위암발병을 33~47% 감소시킨다고 보고하였으나, 중국에서 시행된 무작위 대조 연구에서는 제균 치료가 위암의 전구 병변 감소에 도움이 되지 않았다고 보고하고 있어 위축성 위염이나 장상피화생을 동반한 경우 제균 치료가 위암 예방에 큰 도움이 되지 않을 수 있음을 제시하고 있다. 그렇다면 위축성 위염이 있는 경우가 많은 고령 환자에서는 과연 헬리코박터 제균 치료가 도움이 될 것인가? 저자들은 빅데이터 분석을 통해 헬리코박터 제균 치료가 위암 발병에 미치는 영향을 성별과 연령에 따라 분석하였다. 2003년부터 2012년까지 'Hospital Authority'에 등록된 clarithromycin 포함 3제 요법을 받은 환자들에서의 위암 발생률과 2003년부터 2013년까지 'Hong Kong Cancer Registry'에 등록된 성별과 연령이 일치된 대조군에서의 위암기대 발생률(expected incidence)을 비교하였다. 3제 요법을 받은 73,237명의 환자들을 확인하였을 때, 평균 7.6년의 추적기간 중 200명(0.27%)에서 위암이 발생하였다. 연령에 따라 40세 미만, 40~59세, 60세 이상의 그룹으로 나누어 각각 위암발생률을 대조군과 비교한 결과 60세 이상 환자군에서만 standardized incidence ratio (SIR)가 0.82로 감소하였다. 치료 성공여부에 따라 위암 발생률을 분석하였을 때, 제균 치료에 성공한 60세 이상 군에서 SIR이 0.78로 감소하였으나 재 치료를 받은 40~59세 군에서는 SIR이 2.43으로 증가하였다. 제균 치료시점이 위암 발생률에 미치는 영향으로는 제균 치료 후 10년 미만에서의 위암 발생률에는 큰 영향이 없었으나 10년 이상 경과한 경우 60세 이상 군과 40~59세 군에서의 위암 발병률이 대조군의 위암 예측 발병률보다 낮았다.

A Case Report of the Traditional Korean Treatment of Female Patients with Both Functional Dyspepsia and Chronic Atrophic Gastritis (기능성소화불량과 만성 위축성 위염이 병발된 여성 환자에 대해 한방치료 경험 1례)

  • Yoon, Sang-hyub
    • The Journal of Internal Korean Medicine
    • /
    • v.40 no.4
    • /
    • pp.697-708
    • /
    • 2019
  • Objective: The aim of this study was to introduce gastric dysmotility as a common cause in patients with concurrent functional dyspepsia and chronic atrophic gastritis. Method: Dyspeptic symptoms, the Rydoraku score, gastric motility (electrogastrography, bowel sound analysis), gastric mucosa (gastroendoscopy), and blood and blood chemistry were all evaluated. For the treatment method, Pyengwi-san (solution) and Banwhasashim-tang (extract) were used as herbal drugs. Both ST36 electrical stimulation and simple immersion stimulation of CV11, 12, and 13 in the abdomen were applied. Results: Dyspeptic symptoms including indigestion, headache, and insomnia were all relieved. Gastric myoelectrical activity and gastric pyloric function were additionally improved. The condition of the gastric mucosa was changed from atrophic to erosive. Other side-effects of the treatment were not noted. Conclusion: The traditional Korean treatment showed effectiveness in the relief of dyspeptic symptoms and mucosal improvement of chronic atrophic gastritis. Gastric dysmotility is a common cause of the condition being concurrent with both functional dyspepsia and chronic atrophic gastritis without Helicobacter pylori infection.

Clinical Correlation between the Serum Pepsinogen I/II Ratio and Gastric Cancer (위암환자에서 혈중 Pepsinogen 검사의 의미)

  • Ahn, Dae-Ho;Kang, Hae-Yoon;Kim, Kang-Il;Kim, Se-Hyun;Hong, Sung-Pyo
    • Journal of Gastric Cancer
    • /
    • v.5 no.3 s.19
    • /
    • pp.158-162
    • /
    • 2005
  • Purpose: In order to clarify the carcinogenesis mechanism from chronic atrophic gastritis toward gastric cancer, we measured the pepsinogen I and II and compared their ratio with several clinical findings. Materials and Methods: We measured the preoperative serum pepsinogen I and II by using a radio-immunoassay and compared their ratio with several clinical findings, such as tumor size, mucinous vs non-mucinous tumor, cell differentiation, tumor location, depth of invasion, lymph-node status, Lauren's classification, and peritumoral atrophy in 103 consecutive patients with gastric adenocarcinomas who had received resections at Bundang CHA Hospital during the period from July 2003 to February 2005. Results: There were significant differences in the serum pepsinogen I/II ratio between patients with mucinous vs non-mucinous tumors (n=4 vs 9 and mean pep I/II=1.29 vs. 2.99, p=0.0288), with tumor size more than and less than $10cm^2$ (n=55 vs. 48 and mean pep I/II=2.64 vs. 3.24, p=0.0491), and with or without peritumoral atrophy (n=94 vs. 9 and mean pep I/II=2.83 vs. 3.89, p=0.0466). In patients with peritomoral atrophy, the pepsinogen I/II ratio was also lower in larger tumors (n=48 vs. 46 and mean pep I/II=2.44 vs. 3.23, p=0.0083). Well-differentiated carcinomas showed significantly lower serum pep I/II ratios than signet-ring-ceil types. There was no correlation between serum pep I/II ratio and tumor location, depth of invasion, lymph-node status, or Lauren's classification Conclusion: We proved the existence of a correlation between serum pepsinogen level and musosal atrophy, but these results are not sufficient for clinical application of serum pepsinogen level as a screening tool for gastric cancer.

  • PDF

A Review of Recent Clinical Research about Banhasasim-tang Combined with Conventional Therapy on Atrophic Gastritis (위축성 위염에 대한 반하사심탕과 표준치료 병용요법의 최신 연구 동향)

  • Lee, Ga-young;Ahn, Su-bin;Jeong, Min-jeong;Jang, In-soo
    • The Journal of Internal Korean Medicine
    • /
    • v.40 no.6
    • /
    • pp.1169-1178
    • /
    • 2019
  • Objective: The purpose of this study was to investigate the effect of combined therapy with Banhasasim-tang and conventional treatment for atrophic Gastritis. Methods: The study collected data of clinical studies of combined therapy with Banhasasim-tang and conventional treatment for atrophic gastritis. Electronic databases were used, including PubMed, Cochrane, CNKI, Wanfang, CINII, J-stage, NDSL, and OASIS. The main search terms included such as "Atrophic Gastritis", "Banhasasim-tang", "BanXia Xiexin Tang". This study only included randomized controlled trials (RCTs) that adopted combined therapy with Banhasasim-tang and conventional treatment for atrophic gastritis. Results: A total of 18 RCTs were selected. They all adopted combined therapy with Banhasasim-tang and conventional treatment for atrophic gastritis. In all the studies, the intervention group significantly improved the score of effective rate, and in the 8 studies, Hp negative conversion rate was significantly improved when Banhasasim-tang was taken. Conclusion: Through the analysis of 18 RCTs, we found Banhasasim-tang combined with conventional therapy were more effective in the positive performance of atrophic gastritis than conventional therapy single contribution. However, due to the low quality of the selected studies and the lack of endoscopy, biopsy, follow-up observation, so there is a slight insufficient to prove its conclusion. Therefore, we hope that more systematic and diverse clinical studies will be conducted.

Study on the Effect of Chicken Egg Containing IgY against Helicobacter pylori (항헬리코박터 IgY 항체의 위염(위궤양) 치료효과에 관한 연구)

  • 배만종;김수정;김병기;박창호;서정일;김욱년;장태정;권상호
    • Journal of the Korean Society of Food Science and Nutrition
    • /
    • v.32 no.8
    • /
    • pp.1357-1363
    • /
    • 2003
  • This study was conducted to investigate the effect of chicken egg containing IgY against H. pylori in patients with gastritis. Sixty three H. pylori-infected volunteers (20∼43 year, Male Female=49 : 14) were randomized into four groups which were treated with one chicken egg containing IgY b.i.d. (IgY group; n=17) or omeprazole 20 mg b.i.d., amoxicillin 1.0 g b.i.d. and clarithromycin 500 mg b.i.d. (OAC group; n=17) or omeprazole 20 mg b.i.d., amoxicillin 1.0 g b.i.d., clarithromycin 500 mg b.i.d. and one chicken egg containing IgY b.i.d. (OAC with IgY group; n=16) for 2 weeks or lyophilized IgY 1 g b.i.d (lyophilized IgY group) for 1 month. $\Delta$$^{13}$ $CO_2$ before and after treatment, the eradication rate of H. pylori and histologic change including H. pylori density, acute and chronic inflammation activity, intestinal metaplasia and glandular atrophy by updated sydney system were evaluated. Eradication rate of OAC with IgY group (94%) was higher than IgY group (0%), lyophilized IgY group (0%) and OAC group (88%). $\Delta$$^{13}$ $CO_2$at 2 weeks after treatment in one patient of IgY group was decreased. But that was not changed in the other patients. $\Delta$$^{13}$ $CO_2$ at 1 week after treatment in 15 patients of OAC with IgY group was significantly lower than pretreatment level (p<0.05), and $\Delta$$^{13}$ $CO_2$ at 1 week and 2 week after treatment was decreased in the other patient. Acute inflammation activity at antrum was significantly decreased after treatment in IgY and lyophilized IgY group (p<0.01), H. pylori density at antrum was significantly decreased after treatment in IgY and lyophilized IgY group (p<0.05). Chronic inflammation activity at body was decreased after treatment in lyophilized IgY group. Intestinal metaplasia and glandular atrophy at antrum and body were not changed after treatment in IgY group. Mild intestinal metaplasia in one patient of lyophilized IgY group changed to normal after 1 month treatment. Gandular atrophy at antrum and body were not changed after treatment in lyophilized IgY group.